Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 9, 2000 - Issue 4
Submit an article Journal homepage
209
Views
73
CrossRef citations to date
0
Altmetric
Review

Apoptosis modulators in the therapy of neurodegenerative diseases

Hans-Peter Deigner Institutes of Pharmaceutical Chemistry, University of Heidelberg, Germany.
,
Uwe Haberkorn Clinic of Radiology, Department of Nuclear Medicine, University of Heidelberg, Germany.
&
Ralf Kinscherf Anatomy and Cell Biology III University of Heidelberg, Germany. [email protected]
Pages 747-764 | Published online: 24 Feb 2005

Bibliography

  • UNSICKER K, SUTER-CRAZZALORA C, KRIEGLSTEIN K: Growth factor function in the development and maintenance of midbrain dopaminergic neurones: concepts, facts and prospects for TGF-6. Ciba Found Symp. (1996) 196:70-80 (Discussion 80–84).
  • OLANOW CW, TATTON WG: Etiology and pathogenesis of Parkinson's disease. Ann. Rev. Neurosa (1999) 22:123–144.
  • UNSICKER K: Growth factors in Parkinson's disease. Prog. Growth Factor Res. (1994) 5(1):73–87.
  • MARSDEN CD, OLANOW CW: The causes of Parkinson's disease are being unraveled and rational neuroprotec-tive therapy is close to reality. Ann. Neurol (1998) 44\(Suppl. 0:S189–196.
  • PAHWA R, MARJAMA J, MCGUIRE D et al.: Pharmacoki-netic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. Mov. Disord. (1996) 11(4):427–430.
  • DOOLEY M, MARKHAM A: Pramipexole. A review of its use in the management of early and advanced Parkin-son's disease. Drugs Aging (1998) 12(6):495–514.
  • GOTTWALD MD, BAINBRIDGE JL, DOWLING GA, AMINOFF MJ, ALLDREDGE BK: New pharmacotherapy for Parkinson's disease. Ann. Pharmacother. (1997) 31(10):1205–1217.
  • DA-PRADA M: New approaches to the treatment of age-related brain disorders. Can. J. Neurol Sci. (1991) 18\(Suppl. 3):384–386.
  • BLANCHET PJ: Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives. Can. J. Neurol. Sci. (1999) 26\(Suppl. 2):S21–26.
  • RABEY JM: Second generation of dopamine agonists: pros and cons. J. Neural. Transm. Suppl. (1995) 45:213–224.
  • VILLA RF, ARNABOLD R, GHIGINI B, GORINI A: Parkinson-like disease by 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine (MPTP) toxicity in Macaca fascicularis: synaptosomal metabolism and action of dihydroergocriptine. Neurochem. Res. (1994) 19(3):229–236.
  • STOCCHI F, NORDERA G, MARSDEN CD: Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Neuropharmacol. (1997) 20 (2):95–115.
  • GLENNER CG, WONG CW: Alzheimer's disease and down's syndrome: sharing of a unique cerebrovas-cular amyloid fibril protein) derived by proteolysis of amyloid precursor protein (APP). Biochem. Biophys. Res. Commun. (1984) 122:1131–1135.
  • KANG J, LEMAIRE HG, UNTERBECK A et al.: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 325:733–736.
  • KOH JY, YANG LL, COTMAN CW: Beta-amyloid proteinincreases the vulnerability of cultured cortical neurones to excitotoxic damage. Brain Res. (1990) 533:315–320.
  • MULTHAUP G, SCHLICKSUPP A, HESSE L et al.: Theamyloid precursor protein of Alzheimer's disease in the reduction of copper(I) to copper(0. Science (1996) 271:1406–1409.
  • KRUMAN I, BRUCE-KELLER AJ, BREDESEN D, WAEG G, MATTSON MP: Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. j Neurosa (1997) 17:5089–5100.
  • SAYRE LM, ZELASKO DA, HARRIS PL, PERRY G, SALOMON RG, SMITH MA: 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. (1 9 9 7) 68(2)2092–2097.
  • MARSHALL KA, DANIEL SE, CAIRNS N, JENNER P, HALLIWELL B: Upregulation of the anti-apoptotic protein Bc1-2 may be an early event in neurodegenera-tion: studies on Parkinson's and incidental Lewy body disease. Biochem. Biophys.Res. Commun. (1997) 240(1)84–87.
  • BEDNER E, LI X, GORCZYCA W, MELAMED MR, DARZYNKIEWICZ Z: Analysis of apoptosis by laser scanning cytometry. Cytometty (1999) 35 (3):181–195
  • NICOTERA P, LEIST M, MANZO L: Neuronal cell death: ademise with different shapes. TIPS (1999) 20:46–51.
  • •Critical review including potential risks of anti-apoptotic treatment.
  • DEIGNER HP, KINSCHERF R: Modulating Apoptosis: Current Applications and Prospects for Future Drug Development. Curr. Med. Chem. (1999) 6:399–414.
  • DIXON SC, ARAH IN: Apoptosis: a novel therapeutic tool. Exp. Opin. Invest. Drugs (1998) 7(6):889–904.
  • DENNER L: Caspases in apoptotic death. Exp. Opin. Invest. Drugs (1999) 8(0:37–50.
  • PELENGARIS SA, EVAN GI: Matters of life and cell death. Rev. Neurol. Paris (1997) 153(8-9):470–477.
  • FRIEDLANDER RM, YUAN J: ICE, neuronal apoptosis and neurodegeneration. Cell Death Differ. (1 9 9 8) 5 (10):823–831.
  • OLANOW CW: An introduction of the free radical hypothesis in Parkinson's disease. Ann. Neurol. (1992) 32:S2–S9.
  • GORMAN AM, MCGOWAN A, O'NEILL C, COTTER T: Oxidative stress and apoptosis in neurodegeneration. Neurol Sci. (1996) 139:45–52.
  • MULTHAUP G, RUPPERT T, SCHLICKSUPP A et al.:Reactive oxygen species and Alzheimer's disease. Biochem. Pharmacol. (1997) 54(5)533–539.
  • FRANCE-LANORD V, BRUGG B, MICHEL PP, AGID Y, RUBERG M: Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease. J. Neurochem. (1997) 69(4):1612–1621.
  • TATTON WG, OLANOW CW: Apoptosis in neurodegen-erative diseases: the role of mitochondria. Biochim. Biophys. Acta. (1999) 1410(2):195–213.
  • TEMLETT JA: Parkinson's disease: biology and aetiology. Curr. Opin. Neurol. (1996) 9(4):303–307.
  • TATTON WG, CHALMERS-REDMAN RM: Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? Ann. Neurol (1998) 44 (Suppl. 1):S134–141.
  • WULLNER U, KORNHUBER J, WELLER M et al.: Cell death and apoptosis regulating proteins in Parkinson's disease, a cautionary note. Acta Neuropathol. Bed. (1999) 97 (4):408–412.
  • VYAS S, JAVOY-AGID F, HERRERO MT et al.: Expression of Bc1-2 in adult human brain regions with special reference to neurodegenerative disorders. J. Neurochem. (1997) 69 (1) :223–231.
  • PEROVIC S, BOHM M, MEESTERS E et al.: Pharma-cological intervention in age-associated brain disorders by Flupirtine: Alzheimer's and prion diseases. Mech. Ageing Dev. (1998) 1O1(1–2):1–19.
  • •Opens the perspective of pharmacological treatment of AD by an approved drug.
  • HUNOT S, BRUGG B, RICARD D et al.: Nuclear transloca-tion of NF-kappaB is increased in dopaminergic neurones of patients with Parkinson's disease. Proc. Natl. Acad. Sci. USA (1997) 94(14):7531–7536.
  • HUNOT S, DUGAS N, FAUCHEUX B et al.: Fcepsi-lonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. (1999) 19(9)3440–3447.
  • RUBERG M, FRANCE-LANORD V, BRUGG B et al: Neuronal death caused by apoptosis in Parkinson's disease. Rev. Neurol. Paris. (1997) 153(8-9):499–508.
  • WHITE AR, BUSH Al, BEYREUTHER K, MASTERS CL CAPPAI R: Exacerbation of copper toxicity in primary neuronal cultures depleted of cellular glutathione. Neurochem. (1999) 72(5)2092–2098.
  • •Supports the importance of oxidative stress in the aetiology of AD.
  • FERRARI G, YAN YC, GREENE LA: N-acetylcysteine (D-and L- stereoisomers) prevents apoptotic death of neuronal cells. J. Neurosci. (1995) 15:2857–2866.
  • RATAN RR, MURPHY TH, BARABAN JM: Oxidative stress induces apoptosis in embryonic cortical neurones. J. Neurochem. (1994) 62 (1) :376–379.
  • SEATON TA, COOPER JM, SCHAPIRA AH: Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. (1997) 777(1-2):110–118.
  • KIKUCHI S, SHINPO K, MORIWAKA F, MAKITA Z, MIYATA T, TASHIRO K: Neurotoxicity of methylglyoxal and 3-deoxyglucosone on cultured cortical neurones: synergism between glycation and oxidative stress, possibly involved in neurodegenerative diseases. J. Neurosci. Res. (1999) 57(2):280–289.
  • MARTINEZ M, MARTINEZ N, HERNANDEZ Al, FERRANDIZML: Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease? Life Sci. (1999) 64 (15):1253–1257.
  • PEARCE RK, OWEN A, DANIELS, JENNER P, MARSDEN CD: Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural. Transm. (1997) 104(6-7):661–677.
  • ARIGA T, JARVIS WD, YU RK: Role of sphingolipid-mediated cell death in neurodegenerative diseases. J. Lipid Res. (1998) 39(1):1–16.
  • LUO Y, UMEGAKI H, WANG X, ABE R, ROTH GS: Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. (1998) 273M3756–3764.
  • ZIV I, OFFEND, BARZILAI A et al: Modulation of controlmechanisms of dopamine-induced apoptosis-a future approach to the treatment of Parkinson's disease? J. Neural. Transm. Suppl. (1997) 49:195–202.
  • KITAMURA Y, KOSAKA T, KAKIMURA JI et al.: Protectiveeffects of the antiparkinsonian drugs talipexole and pramipexole against 1-methy1-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. (1998) 54:1046–1054.
  • MORDENTE A, MARTORANA GE, MINOTTI G, GIARDINAB: Antioxidant properties of 2,3-dimethoxy-5-methy1-6-(10-hydroxydecy0-1,4-benzoquinone (idebenone). Chem. Res. Toxicol. (1998) 11(1):54–63.
  • TAKEDA CHEMICAL INDUSTRIES LTD.: Takeda Annual Report 1998. Overview of product status.
  • THAL LJ: Clinical and preclinical information of anti-oxidant: idebenone and vitamin E. Neurobiol. Aging (1998) 19\(Suppl. 4):56.
  • GUTZMANN H, HADLER D: Clinical evaluation of idebenone in the long-term treatment of Alzheimer's disease. Neurobiol. Aging (1998) 19\(Suppl. 4):55.
  • PEREIRA C, SANTOS MS, OLIVEIRA C: Involvement of oxidative stress on the impairment of energy metabo-lism induced by A beta peptides on PC12 cells: protec-tion by antioxidants. Neurobiol Dis. (1999) 6(3)209–219.
  • HIRAI K, HAYAKO H, KATO K, MIYAMOTO M: Idebenone protects hippocampal neurones against amyloid beta-peptide-induced neurotoxicity in rat primary cultures. Naunyn Schmiedebergs Arch. Pharmacol. (1998) 358(5)582–585.
  • CIVENNI G, BEZZI P, TROTTI D, VOLTERRA A, RACAGNI G: Inhibitory effect of the neuroprotective agent idebenone on arachidonic acid metabolism in astrocytes. Eur. j Pharmacol. (1999) 370 (2) :161–167.
  • SCAVINI C, ROZZA A, LANZA E, FAVALLI L, RACAGNI G, BRUNELLO N: Effect of idebenone on in vivo serotonin release and serotonergic receptors in young and aged rats. Eur. Neuropsychopharmacol. (1996) 6(2):95–102.
  • PAPPOLLA MA, CHYAN YJ, BOZNER P et al.: Dual anti-amyloidogenic and antioxidant properties of melatonin: A new therapy for Alzheimer's disease? Alzheimer's Disord. (1999):661–669.
  • PAPPOLLA MA, SOS M, OMAR RA et al.: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci. (1997) 1 7 (5) :1683–1690.
  • TAN DX, MANCHESTER LC, REITER RJ, QI W, KIM SJ,EL-SOKKARY GH: Melatonin protects hippocampal neurones in vivo against kainic acid-induced damage in mice. J. Neurosci. Res. (1998) 54 (3):382–389.
  • SIMONS M, KELLER P, DE-STROOPER B, BEYREUTHER K, DOTTI CG, SIMONS K: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurones. Proc. Natl. Acad. Sci. USA (1 9 9 8) 95(11)6460–6464.
  • HARTMANN T, BIEGER SC, BROHL B et al.: Distinct sites of intracellular production for Alzheimer's disease A 640/42 amyloid peptides. Nature Med. (1997) 3(9):1016–1020.
  • PILLOT T, DROUET B, QUEILLE S et al: The nonfibrillaramyloid 6-peptide induces apoptotic neuronal cell death: involvement of its C-terminal fusogenic domain. J. Neurochem. (1999) 73(4):1626–1634.
  • SCORZIELLO A, MEUCCI 0, CALVANI M, SCHETTINI G: Acetyl-L-carnitine arginine amide prevents beta 25-35-induced neurotoxicity in cerebellar granule cells. Neurochem. Res. (1997) 22(3):257–265.
  • DOBBS RJ, CHARLETT A, PURKISS AG, DOBBS SM, WELLER C, PETERSON DW: Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. (1999) 100(0:34–41.
  • HERR I, WILHELM D, BOHLER T, ANGEL P, DEBATIN KM:Activation of CD95 (APO-1/Fas) signalling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. (1997) 16(20):6200–6208.
  • BERRIDGE MJ: Lymphocyte activation in health anddisease. Grit. Rev. Immunol (1997) 17(2):155–178.
  • MORETTI S, ALESSE E, DI-MARZIO L et al. Effect of L-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: a pilot study. Blood (1998) 9i(10):3817–3824.
  • HERR I, MARTIN-VILLALBA A, KURZ E et al.: FK506prevents stroke-induced generation of ceramide and apoptosis signalling. Brain Res. (1999) 826(2):210–219.
  • CLAUS R, RUSSWURM S, MEISNER M, KINSCHERF R, DEIGNER HP: Modulation of the ceramide level, a novel therapeutic concept? Current Drug Targets (In Press).
  • SUBBARAMA1AH K, CHUNG WJ, DANNENBERG AJ: Ceramide regulates the transcription of cyclooxygenase-2. J. Biol. Chem. (1998) 273:32943–32949.
  • VANE JR, BOTTING RM: Mechanism of action of antiin-flammatory drugs. Int. J. Tissue React. (1998) 20 (1):3–15.
  • PASINETTI GM, AISEN PS: Cyclooxygenase-2 expressionis increased in frontal cortex of Alzheimer's disease brain. Neuroscience (1998) 87 (2):319–324.
  • HO L, PIERONI C, WINGER D, PUROHIT DP, AISEN PS,PASINETTI GM: Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J. Neurosci. Res. (1 9 9 9) 57 (3):295–303.
  • LUKIW WJ, BAZAN NG: Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J. Neurosci. Res. (1998) 53(5):583–592.
  • TOCCO G, FREIRE-MOAR J, SCHREIBER SS, SAKHI SH,AISEN PS, PASINETTI GM: Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp. Neurol. (1997) 144(2)339–349.
  • ROGERS J, KIRBY LC, HEMPELMAN SR et al.: Clinical trialof indomethacin in Alzheimer's disease. Neurology (1993) 43(8):1609–1611.
  • VANE J: Towards a better aspirin. Nature (1994)367(6460):215–216.
  • BREITNER JC, WELSH KA, HELMS MJ et al.: Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine 112 blocking drugs. Neurobiol. Aging (1995) 16(4):523–530.
  • MOLLER HJ: Therapeutic strategies based on immuno-logical hypotheses of Alzheimer's disease. J. Neural. Transm. Suppl. (1998) 54:175–186.
  • STEWART WF, KAWAS C, CORRADA M, METTER EJ: Riskof Alzheimer's disease and duration of NSAID use. Neurology (1997) 48(3):626–632.
  • KITAMURA Y, SHIMOHAMA S, KOIKE H et al.: Increasedexpression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. (1999) 254(3)582–586.
  • O'BANION MK: Cyclooxygenase-2: molecular biology,pharmacology and neurobiology. Grit. Rev. Neurobiol (1999) 13(0:45–82.
  • LIPSKY PE: The clinical potential of cyclooxygenase-2-specific inhibitors. Am. J. Med. (1999) 106(5B):515–575.
  • RICH JB, RASMUSSON DX, FOLSTEIN MF, CARSON KA,KAWAS C, BRANDT J: Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology (1995) 45 (1):51–55.
  • SCHARF S, MANDER A, UGONI A, VAJDA F, CHRISTO-PHIDIS N: A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology (1999) 53(1):197–201.
  • IN'T VELD BA, LAUNER LJ, HOES AW et al.: NSAIDs andincident Alzheimer's disease. The Rotterdam Study. Neurobiol. Aging (1998) 19(6):607–611.
  • BAZAN NG: The neuromessenger platelet-activatingfactor in plasticity and neurodegeneration. Prog. Brain Res. (1998) 118:281–291.
  • DANNHARDT G, KOHL BK: The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. Curr. Med. Chem. (1998) 5(4):253–263.
  • TENNETI L, D'EMILIA DM, TROY CM, LIPTON SA: Role ofcaspases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurones. J. Neurochem. (1998) 71(3)946–959.
  • FRANKIEWICZ T, POTTER B, BASHIR ZI, COLLINGRIDGEGL, PARSONS CG: Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br. J. Pharmacol. (1996) 117 (4):689–697.
  • WENK GL, DANYSZ W, MOBLEY SL: MK-801, memantineand amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmacol. (1995) 293(3):267–270.
  • DI-PAOLA R, UITTI RJ: Early detection of Parkinson'sdisease. Implications for treatment. Drugs Aging (1996) 9(3):159–168.
  • PARSONS CG, DANYSZ W, QUACK G: Memantine is aclinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology (1999) 38(6):735–767.
  • KORNHUBER J, WELLER M: Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implica-tions for neuroprotective pharmacotherapy. Psychiatry (1997) 41(2):135–144.
  • QUACK G, HESSELINK M, DANYSZ W, SPANAGEL R: Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J. Neural. Transm. Suppl. (1995) 46:97–105.
  • MOGI M, TOGARI A, KONDO T et al.: Brain-derivedgrowth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. (1999) 270(0:45–48.
  • LINGOR P, UNSICKER K, KRIEGLSTEIN K: Midbraindopaminergic neurones are protected from radical induced damage by GDF-5 application. J. Neural. Transm. (1999) 106(2):139–144.
  • •Provides the concept of GDF-5 as potential drug for PD treatment.
  • FARKAS LM, JASZAI J, UNSICKER K, KRIEGLSTEIN K: Characterization of bone morphogenetic protein family members as neurotrophic factors for cultured sensory neurones. Neuroscience (1999) 92 (1):227–235.
  • FARKAS LM, SCHEUERMANN S, POHL J, UNSICKER-K, KRIEGLSTEIN K: Characterization of growth/differen-tiation factor 5 (GDF-5) as a neurotrophic factor for cultured neurones from chicken dorsal root ganglia. Neurosci. Lett. (1997) 236(2):120–122.
  • KRIEGLSTEIN K, REUSS B, MAYSINGER D, UNSICKER K: Short communication: transforming growth factor-beta mediates the neurotrophic effect of fibroblast growth factor-2 on midbrain dopaminergic neurones. Eur. j Neurosci. (1998) 10(8):2746–2750.
  • FLANDERS KC, REN RF, LIPPA CF: Transforming growth factor-betas in neurodegenerative disease. Prog. Neurobiol. (1998) 54(0:71–85.
  • SCHOBER A, HERTEL R, ARUMAE U et al. Glial cell line-derived neurotrophic factor rescues target-deprived sympathetic spinal cord neurones but requires transforming growth factor-beta as cofactor in vivo. J. Neurosci. (1999) 19(6):2008–2015.
  • KRIEGLSTEIN K, HENHEIK P, FARKAS L et al Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurones. J. Neurosci. (1998) 18(23):9822–9834.
  • HUTTER-PAIER B, GRYGAR E, WINDISCH M: Death of cultured telencephalon neurones induced by glutamate is reduced by the peptide derivative Cerebrolysin. J. Neural. Transm. Suppl. (1996) 47:267–273.
  • WINDISCH M, GSCHANES A, HUTTER-PATER B: Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J. Neural. Transm. Suppl. (1998) 53:289–298.
  • FRANCIS-TURNER L, VALOUSKOVA V: Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Neurosci. Lett. (1996) 202 (3):193–196.
  • GSCHANES A, WINDISCH M: Early postnatal treatment with peptide preparations influences spatial naviga-tion of young and adult rats. Behav. Brain Res. (1999) 100(1-2):161–166.
  • REINPRECHT I, GSCHANES A, WINDISCH M, FACHBACH G: Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats. Histochem. J. (1999) 31(6)395–401.
  • LOMBARDI VR, WINDISCH M, GARCIA M, CACABELOS R: Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Methods Find Exp. Clin. Pharmacol. (1999) 21(5):331–338.
  • MASLIAH E, ARMASOLO F, VEINBERGS I, MALLORY M, SAMUEL W: Cerebrolysin ameliorates performance deficits and neuronal damage in apolipoprotein E-deficient mice. Pharmacol. Biochem. Behav. (1999) 62 (2):239–245.
  • RUTHER E, RITTER R, APECECHEA M, FREYTAG S, WINDISCH M: Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry (1994) 27(1)32–40.
  • THORNBERRY NA, LAZEBNIK Y: Caspases: enemies within. Science (1998) 281(5380:1312–1326.
  • SHIVERS BD, BOXER PA, KEANE KM et al.: Contribution of the ICE family to neurodegeneration. Ann. NY Acad. ScL (1998) 840:59–64.
  • HAASS C: Apoptosis. Dead end for neurodegeneration? Nature (1999) 399(6733):204–207.
  • •A timely assessment of the chances of anti-apoptotic treatment for neurodegenerative diseases.
  • LEBLANC A, LIU H, GOODYER C, BERGERON C, HAMMOND J: Caspase-6 role in apoptosis of human neurones, amyloidogenesis and Alzheimer's disease. J. Biol. Chem. (1999) 274 (33):23426–23436.
  • CHAN SL, GRIFFIN WS, MATTSON MP: Evidence for caspase-mediated cleavage of AMPA receptor subunits in neuronal apoptosis and Alzheimer's disease. J. Neurosci. Res. (1999) 57(3):315–323.
  • GERVAIS FG, XU D, ROBERTSON GS et al.: Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell (1999) 97(3)395–406.
  • •Highlights the potential of caspase-inhibition for AD treatment.
  • PELLEGRINI L, PASSER BJ, TABATON M, GANJEI JK, D'ADAMIO L: Alternative, non-secretase processing of Alzheimer's beta-amyloid precursor protein during apoptosis by caspase-6 and -8. J. Biol. Chem. (1999) 274(30:21011–21016.
  • NAKAGAWA T, ZHU H, MORISHIMA N et al.: Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-0. Nature (2000) 403:98–103.
  • WEIDEMANN A, PALIGA K, DURRWANG U et al.: Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and beta-amyloid precursor protein. Nature Med. (1997) 3 (3):328–332.
  • KIM TW, PETTINGELL WH, JUNG YK, KOVACS DM, TANZI RE: Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science (1997) 277(5324)373–376.
  • TANZI RE: Of calcium, caspases and cognitive decline. Nature Med. (1998) 4(10:1127–1178.
  • WOLFE MS, XIA W, OSTASZEWSKI BL, DIEHL TS, KIMBERLY WT, SELKOE DJ: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature (1999) 398(6727):513–517.
  • DIEHLMANN A, IDA N, WEGGEN S et al.: Analysis of presenilin 1 and presenilin 2 expression and processing by newly developed monoclonal antibodies. J. Neurosci. Res. (1999) 56(0405–419.
  • UETSUKI T, TAKEMOTO K, NISHIMURA I etal.: Activation of neuronal caspase-3 by intracellular accumulation of wild-type Alzheimer amyloid precursor protein. J. Neurosci. (1999) 19(16)6955–6964.
  • HOLTZMAN DM, DESHMUKH M: Caspases: a treatment target for neurodegenerative disease? Nature Med. (1997) 3(9):954–955.
  • SCHIERLE GS, HANSSON 0, LEIST M, NICOTERA P, WIDNER H, BRUNDIN P: Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nature Med. (1999) 5(0:97–100.
  • FINK K, ZHU J, NAMURA S et al.: Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation. J. Cereb. Blood Flow Metab. (1998) 18(101071–1076.
  • AKAO Y, NAKAGAWA Y, MARUYAMA W, TAKAHASHI T, NAOI M: Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, is mediated by activation of caspase 3. Neurosci. Lett. (1999) 267 (3):153–156.
  • HOUENOU LJ, TURNER PL, LI L, OPPENHEIM RW, FESTOFF BW: A serine protease inhibitor, protease nexin I, rescues motoneurons from naturally occurring and axotomy-induced cell death. Proc. Natl. Acad. ScL USA (1995) 92(3):895–899.
  • MOURADIAN MM, CHASE TN: Gene therapy for Parkin-son's disease: an approach to the prevention or pallia-tion of levodopa-associated motor complications. Exp. Neurol. (1997) 144:51–57.
  • KANG UJ: Potential of gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies. Mov. Disord. (1998) 13 (Suppl. 1)59–72.
  • GOLLAPUDI L, OBLINGER MM: STable transfection of PC12 cells with estrogen receptor (ERalpha): protec-tive effects of estrogen on cell survival after serum deprivation. J. Neurosci. Res. (1999) 56:99–108.
  • LINNIK MD, ZAHOS P, GESCHWIND MD, FEDEROFF HJ: Expression of bc1-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke (1995) 26: 1670-1674.
  • DE STROOPER B, ANNAERT W, CUPERS P et al.: A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 398 (6727):518–522.
  • SELKOE DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 399(6738 Suppl):A23–31.
  • •Recognises the role of advancements in cell biology for AD treatment.
  • LYSAGHT MJ, FRYDEL B, GENTILE F, EMERICH D, WINN S: Recent progress in immunoisolated cell therapy. J. Biochem. (1994) 56(2):196–203.
  • BEAL MF, GROWDON JH: CSF neurotransmitter markers in Alzheimer's disease. Prog. Neuropsychophar-macol. Biol. Psychiatry (1986) 10:259–270.
  • DESHMUKH M, JOHNSON EM: Programmed cell death in neurones: focus on the pathway of nerve growth factor deprivation-induced death of sympathetic neurones. Mol. Pharmacol (1997) 51 (6)897–906.
  • MOLLER JC, SAUTTER J, KUPSCH A: Potential of neurotrophic factors in therapy of Parkinson's disease. J. Neural. Transm. Suppl. (1996) 48:103–112.
  • KOLIATOS VE: Biological therapies for Alzheimer's disease: focus on trophic factors. Neurobiol. (1996) 10(2)205–238.
  • SCHINSTINE M, FIORE DM, WINN SR, EMERICH DF: Polymer-encapsulated Schwannoma cells expressing human nerve growth factor promote the survival of cholinergic neurones after a fimbria-fornix transec-tion. Cell Transplantation (1995) 4(1):93–102.
  • WINN SR, HAMMANG JP, EMERICH DF, LEE A, PALMITER RD, BAETGE EE: Polymer-encapsulated cells geneti-cally modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurones. Proc. Natl. Acad. Sci. USA (1 9 9 4) 91(6):2324–2328.
  • EMERICH DF, WINN SR, HARPER J, HAMMANG JP, BAETGE EE, KORDOWER JH: Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degener-ating cholinergic basal forebrain neurones. J. Comp. Neurol (1994) 349(0:148–164.
  • KORDOWER JH, WINN SR, LIU YT et al.: The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurones after grafts of encapsulated cells secreting human nerve growth factor. Proc. Natl. Acad. Sci. USA (1994) 91(23):10898–10902.
  • HOFFMAN D, BREAKFIELD XO, SHORT MP, AEBISCHER P: Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Exp. Neurol. (1993) 122(0:100–106.
  • EMERICH DF, WINN SR, HAMMANG JP, KORDOWER JH, FRYDEL BR, BAETGE EE: Transplantation of polymer-encapsulated cells genetically modified to secrete human nerve growth factor prevents the loss of degenerating cholinergic neurones in rats and nonhuman primates. Cell Transplantation (1994) 3 (3):212.
  • CYTOTHERAPEUTICS: Update on core delivery system technologies. London, UK. IDdb Meeting Report (April 15, 1997).
  • WINN SR, LINDNER MD, LEE A, HAGGETT G, FRANCIS JM, EMERICH DF: Polymer-encapsulated genetically modified cells continue to secrete human nerve growth factor for over one year in rat ventricles: behavioral and anatomical consequences. Exp. Neurol. (1996) 140(2):126–138.
  • MIDDLEMISS PJ, GLASKY AJ, RATHBONE MP, WERSTUIK E, HINDLEY S, GYSBERS J: AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells. NeuroscL Lett. (1995) 199(2):131–134.
  • KINSCHERF R, CLAUS R, WAGNER M et al.: Apoptosis caused by oxidized LDL is manganese superoxide dismutase and p53 dependent. FASEB J. (1998) 12 (6):461–467.
  • CIFONE MG, ALESSE E, DI-MARZIO L et al. Effect of L-carnitine treatment in vivo on apoptosis and ceramide generation in peripheral blood lymphocytes from AIDS patients. Proc. Assoc. Am. Physicians (1997) 109(2):146–153.
  • DI-MARZIO L, ALESSE E, RONCAIOLI P et al.: Influence of L-carnitine on CD95 cross-lining-induced apoptosis and ceramide generation in human cell lines: correla-tion with its effects on purified acidic and neutral sphingomyelinases in vitro. Proc. Assoc. Am. Physicians (1997) 109(2):154–163.
  • ANDRIEU-ABADIE N, JAFFREZOU JP, HATEM S, LAURENT G, LEVADE T, MERCADIER JJ: L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. FASEB J. (1999) 13(12):1501–1510.
  • BROOKS JO 3RD, YESAVAGE JA, CARTA A, BRAVI D: Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int. Psychogeriatr. (1998) 10(2):193–203.
  • Riluzole for amyotrophic lateral sclerosis. Drug Ther. Bull. (1997) 35(2):11–12.
  • BENAVIDES J, CAMELIN JC, MITRANI N et al.: 2-Amino-6-trifluoromethoxy benzothiazole, a possible antago-nist of excitatory amino acid neurotransmission. II. Biochemical properties. Neuropharmacology (1985) 24:1085–1092.
  • BENOIT E, ESCANDE D: Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch. (1991) 419:603–609.
  • MAGYAR K, SZENDE B, LENGYEL J, TARCZALI J, SZATMARY I: The neuroprotective and neuronal rescue effects of (-)-deprenyl. J. Neural. Transm. Suppl. (1998) 52:109–123.
  • TATTON WG, CHALMERS-REDMAN RM, JU WY, WADIA J, TATTON NAJ: Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. Neural. Transm. Suppl. (1997) 49:245–268.
  • KRAGTEN E, LALANDE I, ZIMMERMANN K et al.: Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J. Biol. Chem. (1998) 2 73(105821–5828.
  • Novel furan sulphonic acid derivatives for the treatment of neurodegenerative and immunoinflam-matory disorders. Exp Opin. Ther. Patents (1999) 9(10):1427–1429.
  • FOSTER BA, COFFEY HA, MORIN MJ, RASTINEJAD F: Pharmacological rescue of mutant p53 conformation and function. Science (1999) 286:2507–2510.
  • •Supports the novel concept of therapy by conformational stabilisation.
  • XU X, YANG D, WYSS-CORAY T et al.: Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA (1999) 96(13):7547–7552.
  • LEIST M, SINGLE B, CASTOLDI AF, KUHNLE S, NICOTERA P: Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med. (1997) 185(8):1481–1486.
  • EGUCHI Y, SHIMIZU S, TSUJIMOTO Y: Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res. (1997) 57:1835–1840.
  • GARLAND JM, HALESTRAP A: Energy metabolism during apoptosis. J. Biol. Chem. (1997) 272:4680–4688.
  • KAN 0, BALDWIN SA, WHETTON AD: Apoptosis is regulated by the rate of glucose transport in an Interleukin 3 dependent cell line. J. Exp. Med. (1994) 180:917–923.
  • HARRISON PM, CHAN HS, PRUSINER SB, COHEN FE: Thermodynamics of model prions and its implica-tions for the problem of prion protein folding. J. Mol. Biol. (1999), 286 (2) :593–606.
  • PAIK SR, SHIN HJ, LEE JH, CHANG CS, KIM J: Copper OD -induced self-oligomerization of alpha-synuclein. Biochem. J. (1999) 340 (Pt 3):821–828.
  • EL-AGNAF OM, JAKES R, CURRAN MD et al: Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBSLett. (1998) 440(1–2)71–75.
  • MARKESBERY WR, CARNEY JM: Oxidative alterations in Alzheimer's disease. Brain. Pathol. (1999) 9 (1) :133–146.
  • MCGEER PL, MCGEER EG: Mechanisms of cell death in Alzheimer's disease - immunopathology. J. Neural. Transm. Suppl. (1998) 54:159–166.
  • GUEGAN C, CEBALLOS-PICOT I, CHEVALIER E, NICOLE A, ONTENIENTE B, SOLA B: Reduction of ischemic damage in NGF-transgenic mice: correlation with enhance-ment of antioxidant enzyme activities. Neurobiol. Dis. (1999) 6(3):180–189.
  • CRUZ-AGUADO R, FRANCIS-TURNER L, DIAZ-SUAREZ CM, BERGADO J: NGF prevents changes in rat brain glutathione-related enzymes following transection of the septohippocampal pathway. Neurochem. Int. (1999) 34 (2) :125–130.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.